| Bioactivity | CPL207280 is an orally active GPR40/FFA1 agonist with an antidiabetic effect. CPL207280 can effectively enhance glucose-stimulated insulin secretion and improve glucose tolerance in MIN6 pancreatic β-cells as well as in healthy Wistar Han rats and diabetic rat models. CPL207280 can be used for the research of type 2 diabetes[1][2]. |
| In Vivo | CPL207280 (10 mg/kg; 口服 ; 单剂量) 在 Wistar Han 大鼠中具有降血糖的作用，其 (3 mg/kg; 口服; 单剂量) 药代动力学参数 Cmax、Tmax 和 T1/2 分别为 1699 ng/mL、1 h 和 1.41 h[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| CAS | 2361497-72-3 |
| Formula | C18H22O3 |
| Molar Mass | 286.37 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Mach M, et al. Discovery and development of CPL207280 as new GPR40/FFA1 agonist. Eur J Med Chem. 2021;226:113810. [2]. Bazydlo-Guzenda K, et al. CPL207280-a novel GPR40/FFA1-specific agonist shows a favorable safety profile and exerts anti-diabetic effects in type 2 diabetic animals[J]. Molecular Pharmacology, 2021. |